Ardelyx Inc.
34175 Ardenwood Boulevard
Suite 100
Fremont
California
94555
United States
Tel: 510-745-1700
Website: http://www.ardelyx.com/
213 articles with Ardelyx Inc.
-
Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/2/2023
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
-
Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
2/27/2023
Ardelyx, Inc. today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a GI/Microbiome panel discussion at the Cowen 43rd Annual Health Care Conference on Monday March 6, 2023 at 9:10 A.M. Eastern Time in Boston, MA.
-
Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023Conference call scheduled for 4:30 p.m. Eastern Time
2/23/2023
Ardelyx, Inc. today announced it will hold a conference call on Thursday, March 2, 2023, at 4:30 p.m. Eastern Time to discuss fourth quarter and full year 2022 financial results and provide a business update.
-
Ardelyx, Inc. Reports Employment Inducement Grants - February 02, 2023
2/2/2023
Ardelyx, Inc. announced that on January 27, 2023, the compensation committee of the company's board of directors granted 23 new non-executive employees options to purchase an aggregate of 614,064 shares of the company's common stock, and an aggregate of 236,333 Restricted Stock Units.
-
FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
12/29/2022
Ardelyx, Inc. announced that the Office of New Drugs, Center for Drug Evaluation and Research of the U.S. Food and Drug Administration granted the appeal to the Complete Response Letter for the New Drug Application for XPHOZAH.
-
Ardelyx, Inc. Reports Employment Inducement Grants - December 23, 2022
12/23/2022
Ardelyx, Inc. announced that on December 16, 2022, the compensation committee of the company's board of directors granted 17 new non-executive employees options to purchase an aggregate of 271,735 shares of the company's common stock, and an aggregate of 123,375 Restricted Stock Units.
-
Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
12/17/2022
Ardelyx, Inc., a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, provided an update regarding the appeal to the Complete Response Letter for the New Drug Application for XPHOZAH.
-
Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference
11/22/2022
Ardelyx, Inc. today announced that management will participate in a fireside discussion at the 34th Annual Piper Sandler Healthcare Conference.
-
Ardelyx has moved one step closer to the possible approval of its experimental chronic kidney disease drug tenapanor following a favorable 9-4 vote from an FDA advisory committee.
-
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
11/16/2022
Ardelyx, Inc. (Nasdaq: ARDX) today announced the vote of the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting for XPHOZAH for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
-
Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
11/16/2022
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Nasdaq has halted trading of the Company's common stock.
-
The FDA raised doubts about the future of Ardelyx's experimental chronic kidney disease drug tenapanor in briefing documents released ahead of a Wednesday advisory committee meeting.
-
National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels
11/4/2022
Ardelyx, Inc. in partnership with the National Kidney Foundation, announced results from a survey of patients with chronic kidney disease on dialysis conducted to better understand patients' experience managing serum phosphorus levels.
-
Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights
11/3/2022
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business updates and financial results for the third quarter ended September 30, 2022.
-
Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with CKD on Dialysis
11/3/2022
Ardelyx, Inc. announced that new analyses of data from its three Phase 3 trials supporting the clinical utility of XPHOZAH will be presented at the American Society of Nephrology Kidney Week 2022, taking place in Orlando, Florida from November 3-6, 2022.
-
Ardelyx, Inc. Reports Employment Inducement Grants - November 02, 2022
11/2/2022
Ardelyx, Inc. announced that on October 26, 2022, the compensation committee of the company's board of directors granted three new non-executive employees options to purchase an aggregate of 127,907 shares of the company's common stock, and an aggregate of 31,875 Restricted Stock Units.
-
On Nov. 16, the FDA's Cardiovascular and Renal Drug Advisory Committee will meet to discuss the relative merits of Ardelyx’s tenapanor in chronic kidney disease.
-
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan
10/31/2022
Ardelyx, Inc. today announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) for tenapanor for the improvement of hyperphosphatemia in adult patients with chronic kidney disease (CKD) on dialysis.
-
Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022
10/27/2022
Ardelyx, Inc. today announced that it will hold a conference call on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time to review third quarter 2022 financial results and provide a business overview.
-
Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting
10/24/2022
Ardelyx, Inc. (Nasdaq: ARDX) today announced that post-hoc analyses from its Phase 3 T3MPO trials will be presented in two posters at the 2022 American College of Gastroenterology Annual Scientific Meeting (ACG 2022) taking place in Charlotte, North Carolina from October 21-26, 2022 and virtually.